SCHEMBL6500238

SCHEMBL6500238

Cc1ccc(C(=O)Nc2ccc(NCCc3cscn3)cc2)c(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GCGR P47871 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 1/20 0.42
HSD17B10 Q99714 1/20 0.42
POLB P06746 1/20 0.41
APOB P04114 1/20 0.41
MTTP P55157 1/20 0.41
DGAT2 Q96PD7 1/20 0.40
TRPV1 Q8NER1 4/20 0.40
PTPN1 P18031 1/20 0.40
KIT P10721 1/20 0.40
NPC1 O15118 1/20 0.39
GMNN O75496 1/20 0.39
LMNA P02545 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
HTR1A P08908 1/20 0.39
THRB P10828 1/20 0.39
PIM1 P11309 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6488636 0.93 APOB (0.48) GCGRSMN1; SMN2KDM4EHSD17B10POLB
SCHEMBL6488114 0.93 GCGR (0.46) GCGRSMN1; SMN2KDM4ENPC1TP53
SCHEMBL6789936 0.87 ADAMTS7 (0.49) SMN1; SMN2APOBMTTPTRPV1
SCHEMBL6498250 0.86 POLB (0.49) GCGRSMN1; SMN2KDM4EPOLBPTPN1
SCHEMBL6501243 0.85 NPC1 (0.39) GCGRSMN1; SMN2KDM4EAPOBMTTP
SCHEMBL6488178 0.85 SMO (0.52) APOBMTTPTRPV1
SCHEMBL6492802 0.84 POLB (0.47) GCGRSMN1; SMN2KDM4EPOLBPTPN1
SCHEMBL6492299 0.83 APOB (0.39) GCGRSMN1; SMN2KDM4EHSD17B10APOB
SCHEMBL6788446 0.83 KMT2A (0.46) SMN1; SMN2KDM4EHSD17B10POLBNPC1
SCHEMBL6503526 0.82 TRPV1 (0.43) GCGRAPOBMTTPTRPV1KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 GCGR 1784/4885SMN1; SMN2 1921/4885KDM4E 2286/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.